$PLX
Protalix BioTherapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013560 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $14.18M $8.753M $16.09M
YoY Change 17.66% 36.19% 42.09%
Cost Of Revenue $7.074M $4.087M $6.034M
YoY Change 91.03% -13.65% 26.63%
Gross Profit $7.109M $4.666M $10.05M
YoY Change -14.87% 175.44% 53.33%
Gross Profit Margin 50.12% 53.31% 62.49%
Selling, General & Admin $2.848M $2.611M $3.154M
YoY Change -3.59% -17.66% 0.51%
% of Gross Profit 40.06% 55.96% 31.38%
Research & Development $7.386M $7.579M $8.767M
YoY Change 1.43% -1.43% 23.1%
% of Gross Profit 103.9% 162.43% 87.23%
Depreciation & Amortization $270.0K $270.0K $270.0K
YoY Change -6.9% -3.57% -5.59%
% of Gross Profit 3.8% 5.79% 2.69%
Operating Expenses $10.23M $10.19M $11.92M
YoY Change -0.02% -6.17% 16.19%
Operating Profit -$3.125M -$5.524M -$1.870M
YoY Change 65.78% -39.73% -49.53%
Interest Expense -$440.0K $190.0K -$420.0K
YoY Change -80.95% -109.13% -76.92%
% of Operating Profit
Other Income/Expense, Net -$442.0K $190.0K -$416.0K
YoY Change -80.9% -109.16% -77.16%
Pretax Income -$3.570M -$5.334M -$2.286M
YoY Change -15.0% -52.54% -58.28%
Income Tax
% Of Pretax Income
Net Earnings -$3.567M -$5.334M -$2.286M
YoY Change -15.05% -52.55% -58.25%
Net Earnings / Revenue -25.15% -60.94% -14.21%
Basic Earnings Per Share -$0.07 -$0.11 -$0.05
Diluted Earnings Per Share -$0.07 -$0.11 -$0.05
COMMON SHARES
Basic Shares Outstanding 49.75M 47.33M 45.84M
Diluted Shares Outstanding 49.50M 47.33M 45.84M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.70M $12.50M $16.90M
YoY Change 0.94% -63.13% -14.65%
Cash & Equivalents $10.72M $12.49M $16.89M
Short-Term Investments
Other Short-Term Assets $1.736M $2.597M $1.123M
YoY Change -23.66% -13.81% -35.97%
Inventory $14.56M $16.51M $16.59M
Prepaid Expenses
Receivables $8.651M $2.022M $5.908M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.76M $49.70M $56.54M
YoY Change -35.75% -48.19% -37.66%
LONG-TERM ASSETS
Property, Plant & Equipment $4.677M $4.768M $4.894M
YoY Change -7.66% -4.47% 1.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $1.400M $2.100M
YoY Change -26.32% -26.32% 16.67%
Total Long-Term Assets $10.95M $10.94M $11.85M
YoY Change -10.68% -10.92% -2.03%
TOTAL ASSETS
Total Short-Term Assets $45.76M $49.70M $56.54M
Total Long-Term Assets $10.95M $10.94M $11.85M
Total Assets $56.71M $60.64M $68.39M
YoY Change -32.07% -43.96% -33.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.600M $7.000M $7.900M
YoY Change -33.33% 14.75% 23.44%
Accrued Expenses $1.000M $1.100M $1.200M
YoY Change -16.67% -8.33% -14.29%
Deferred Revenue $14.79M $10.22M $11.80M
YoY Change -2.42% -43.55% 360.98%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.30M $30.96M $35.33M
YoY Change -19.79% -67.83% -56.31%
LONG-TERM LIABILITIES
Long-Term Debt $28.10M $28.00M $28.00M
YoY Change 1.08%
Other Long-Term Liabilities $5.800M $11.50M $12.60M
YoY Change -54.33% 30163.16% 48361.54%
Total Long-Term Liabilities $33.92M $39.57M $40.55M
YoY Change -16.25% 387.54% 445.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.30M $30.96M $35.33M
Total Long-Term Liabilities $33.92M $39.57M $40.55M
Total Liabilities $68.22M $70.53M $75.88M
YoY Change -18.07% -32.42% -14.06%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.51M -$9.889M -$7.486M
YoY Change
Total Liabilities & Shareholders Equity $56.71M $60.64M $68.39M
YoY Change -32.07% -43.96% -33.47%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.567M -$5.334M -$2.286M
YoY Change -15.05% -52.55% -58.25%
Depreciation, Depletion And Amortization $270.0K $270.0K $270.0K
YoY Change -6.9% -3.57% -5.59%
Cash From Operating Activities -$9.200M -$7.360M -$5.829M
YoY Change 389.36% -213.06% -40.73%
INVESTING ACTIVITIES
Capital Expenditures $60.00K $130.0K $229.0K
YoY Change -82.35% -53.57% -40.67%
Acquisitions
YoY Change
Other Investing Activities $5.970M $490.0K $28.00K
YoY Change 19.88% -93.73% 0.0%
Cash From Investing Activities $5.910M $360.0K -$16.26M
YoY Change 27.92% -95.23% -47.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.520M 2.640M
YoY Change -105.85%
NET CHANGE
Cash From Operating Activities -9.200M -7.360M -5.829M
Cash From Investing Activities 5.910M 360.0K -16.26M
Cash From Financing Activities 1.520M 2.640M
Net Change In Cash -1.770M -4.360M -22.10M
YoY Change -92.39% -131.03% -1511.95%
FREE CASH FLOW
Cash From Operating Activities -$9.200M -$7.360M -$5.829M
Capital Expenditures $60.00K $130.0K $229.0K
Free Cash Flow -$9.260M -$7.490M -$6.058M
YoY Change 317.12% -220.22% -40.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46589976
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42744426
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47327952
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45436907
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
696-9345
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3442000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2597000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1285000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16507000
us-gaap Other Income
OtherIncome
51000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
49700000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
61666000
CY2022Q2 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1403000
CY2021Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2077000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4768000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4962000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4769000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4960000
CY2022Q2 us-gaap Assets
Assets
60640000
CY2021Q4 us-gaap Assets
Assets
73665000
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6991000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6986000
CY2022Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
12663000
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
16433000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1083000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1207000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3171000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7394000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10223000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8550000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30960000
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49753409
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12492000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38985000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6309000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2611000
CY2022Q2 plx Short Term Bank Deposits
ShortTermBankDeposits
16082000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2022000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33176000
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28033000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27887000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5895000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11790000
CY2022Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1748000
CY2021Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2472000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3893000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4376000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
39569000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46525000
CY2022Q2 us-gaap Liabilities
Liabilities
70529000
CY2021Q4 us-gaap Liabilities
Liabilities
79701000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-9889000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60640000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73665000
us-gaap Revenues
Revenues
24838000
us-gaap Revenues
Revenues
17747000
CY2022Q2 us-gaap Revenues
Revenues
8753000
CY2021Q2 us-gaap Revenues
Revenues
6427000
us-gaap Cost Of Revenue
CostOfRevenue
10121000
us-gaap Cost Of Revenue
CostOfRevenue
9498000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
4087000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
4733000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16346000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14811000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7579000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7689000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5765000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12871000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5524000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9166000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1242000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4240000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
623000
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2203000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1016000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
344000
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
813000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
128000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-226000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3896000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
190000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2075000
us-gaap Net Income Loss
NetIncomeLoss
-7620000
us-gaap Net Income Loss
NetIncomeLoss
-16716000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5334000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11241000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46589976
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42744426
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47327952
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45436907
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
832000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
562000
us-gaap Net Income Loss
NetIncomeLoss
-16716000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
2641000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
293000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
831000
plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
2000
us-gaap Net Income Loss
NetIncomeLoss
-7620000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-9889000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14504000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
322000
CY2021Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
256000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11241000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-7486000
CY2022Q2 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
2641000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144000
CY2022Q2 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
144000
CY2022Q2 plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
2000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5334000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-9889000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
us-gaap Profit Loss
ProfitLoss
-7620000
us-gaap Profit Loss
ProfitLoss
-16716000
us-gaap Share Based Compensation
ShareBasedCompensation
1124000
us-gaap Share Based Compensation
ShareBasedCompensation
1394000
us-gaap Depreciation
Depreciation
538000
us-gaap Depreciation
Depreciation
574000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
952000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
121000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-449000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
70000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-16000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
56000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
146000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1928000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2644000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12268000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-76000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1587000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
3000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-94000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1447000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
558000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4864000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-544000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-13000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13185000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3318000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
16000000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
15000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
357000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
667000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-359000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-457000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
54000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15900000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23144000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37625000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2641000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2643000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42114000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-51000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-35000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26493000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15617000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38985000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18265000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12492000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33882000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
81000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
372000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
99000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
232000
us-gaap Interest Paid Net
InterestPaidNet
1120000
us-gaap Interest Paid Net
InterestPaidNet
2172000
plx Interest Received Net
InterestReceivedNet
93000
plx Interest Received Net
InterestReceivedNet
307000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32960732
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32982043
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25874641
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26322164
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3304000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3166000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3296000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3262000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9907000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11526000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16507000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000

Files In Submission

Name View Source Status
0001558370-22-013560-index-headers.html Edgar Link pending
0001558370-22-013560-index.html Edgar Link pending
0001558370-22-013560.txt Edgar Link pending
0001558370-22-013560-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20220630.xsd Edgar Link pending
plx-20220630x10q.htm Edgar Link pending
plx-20220630x10q005.jpg Edgar Link pending
plx-20220630x10q006.jpg Edgar Link pending
plx-20220630x10q007.jpg Edgar Link pending
plx-20220630xex31d1.htm Edgar Link pending
plx-20220630xex31d2.htm Edgar Link pending
plx-20220630xex32d1.htm Edgar Link pending
plx-20220630xex32d2.htm Edgar Link pending
plx-20220630xex3d5.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
plx-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
plx-20220630_pre.xml Edgar Link unprocessable
plx-20220630_def.xml Edgar Link unprocessable
plx-20220630x10q_htm.xml Edgar Link completed
plx-20220630_lab.xml Edgar Link unprocessable